Novartis Bids On "Superstatin": Seeking U.S. Rights To Pitavastatin
Novartis is in negotiations for the U.S. rights to pitavastatin with Sankyo and Nissan Chemicals, CEO Daniel Vasella, MD, told the New York Society of Securities Analysts June 5.
Novartis is in negotiations for the U.S. rights to pitavastatin with Sankyo and Nissan Chemicals, CEO Daniel Vasella, MD, told the New York Society of Securities Analysts June 5.